Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

NCT07644897 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Immune-related Adverse Event
Immune Checkpoint Inhibitor

Interventions

DRUG: Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody

Sponsor

Sun Yat-sen University